Role of NF-κB Signaling Pathway in Osteosarcoma Volume 6 - Issue 1

Peng Cheng^1,2,3, Hai-Yang Liao^1,2,3 and Hai-hong Zhang¹*

• ¹The Second Clinical Medical College, Lanzhou University, China
• ²Department of Orthopaedics, Lanzhou University Second Hospital, China
• ³Orthopaedics Key Laboratory of Gansu Province, China

Received: December 21, 2021   Published: January 24, 2022

*Corresponding author: Hai-hong Zhang, The Second Clinical Medical College, Lanzhou University, China

DOI: 10.32474/LOJMS.2022.06.000230

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Osteosarcoma (OS) is the most common bone malignancy in children and adolescents. Despite the efficacy of multiscientific and multimodal therapies for OS, the prognosis of OS is not satisfactory, which highlights the need to find more effective therapies. The NF-κB pathway is a highly complex and unique intracellular signaling pathway, whose abnormal expression has been implicated in a variety of human diseases, including cancer, spinal cord injury, degenerative disc changes, traumatic brain injury, and tuberculosis. NF-κB pathway is considered to be a common signaling pathway in human cancer. Multiple studies have shown that this pathway is often abnormally expressed in OS and regulates the pathophysiological processes of osteosarcoma, such as gene expression, cell proliferation and apoptosis, invasion, migration and tumor angiogenesis. Therefore, manipulation of the expression or function of the associated NF-κB pathway may be a potential clinical target for treating OS. In this review, we summarize the characteristics of the NF-κB signaling pathway and its role in the pathogenesis and development of OS, as well as the current research mechanisms of compounds that inhibit or target the NF-κB pathway in OS

Keywords: NF-κB Pathway; Osteosarcoma; Tumogenesis; Therapeutic Target; Apoptosis

Abstract| Introduction| Overview of NF-κB Pathway| Role of NF-κB pathway in OS| Interaction Between NF-κB Pathway and LncRNA in OS| Natural Inhibitor of NF-κB Pathway| Discussion| References|